In this interview, Eric Klaver, the DCT regulatory director for decentralized clinical trials at IQVIA, aiding in compliance of the DCT strategy and platform, shares how IQVIA supports investigators within the areas of clinical trial conduct and operations.
IQVIA is a leading global provider of advanced analytics technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility, enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients.
Decentralized trials leverage technology and specialized services to engage participants. IQVIA facilitates patient-centric care within trials by including elements such as remote pre-screening, telemedicine visits, at home treatments, mobile research nurses and site-specific support.
As a whole, our industry is modernizing its current practices with elements of DCT rather than taking a major shift in how trials are conducted. None the less, this involves the use of systems and significant technology incorporation, but regulations on system security, privacy, and confidentiality must be considered throughout implementation.
IQVIA provides trained, dedicated staff based on the site’s requirements and study needs. These roles provide a specialty resource solution that is customized to your site – where and when it is needed – to manage day-to-day clinical trial tasks.
By understanding the best ways of utilizing decentralized elements in clinical trials, sites and participants become familiar with these study elements, giving a access to a more personalized, patient-centric trial experience.
Listen below